| Document |
Document Title |
|
WO/2024/096818A1 |
The present disclosure relates generally to compositions for enhancing mental wellbeing, particularly compositions from plant extracts for use in calming energizing or enhancing happiness or euphoria in individuals. Methods disclosed inc...
|
|
WO/2024/096133A1 |
The present invention provides a cell-to-cell human T-lymphotropic virus type 1 (HTLV-1) infection inhibitor that contains a substance that inhibits interaction between N-acetyllactosamine (LacNAc) and galectin-3 (Gal-3).
|
|
WO/2024/096418A1 |
The present invention relates to a pharmaceutical or cosmetics composition having anti-inflammatory, anti-pruritic, anti-allergenic, and deodorant effect, the composition comprising composite extract of Lagerstroemia indica and Persicari...
|
|
WO/2024/095992A1 |
The present invention addresses the problem of providing a novel means for suppressing renal hypofunction, the means being capable of fundamentally improving diseases associated with renal hypofunction, including chronic kidney disease (...
|
|
WO/2024/096124A1 |
The present disclosure provides a microorganism that inhibits oligomer formation of sgA. More specifically, the present disclosure provides a microorganism wherein at least one gene among the curli pili operon gene group, sigma factor ge...
|
|
WO/2024/097571A1 |
Disclosed are compositions and methods for using heme and at least one PAMP and/or DAMP molecule for activating NLRP12 and/or NLRC5 and inflammatory cell death. Also provided is a screening assay for identifying NLRP12 and/or NLRC5 inhib...
|
|
WO/2024/094098A1 |
Provided in the present application are a compound for a delivery system and the use thereof, and an ionizable lipid having a hydrogen bond providing group.
|
|
WO/2024/095793A1 |
[Problem] To provide an antioxidant cosmetic. [Solution] Provided is an antioxidant cosmetic containing at least one component selected from the group consisting of (A) a cyclic carboxamide derivative having a specific structure or a sal...
|
|
WO/2024/095158A1 |
Disclosed are uses of an orexin type 2 receptor (OX2R) agonist at non-awakening concentrations. Also disclosed are compositions and methods for administering an OX2R agonist to a subject (e.g., mammal) in need thereof at a dose that prov...
|
|
WO/2024/096121A1 |
The present disclosure provides a bacterial preparation that can be used to treat inflammatory bowel disease. More specifically, the present disclosure relates to a microorganism in which a gene from at least one of a fimbria operon gene...
|
|
WO/2024/097131A1 |
The present disclosure provides a clinically applicable method to re-balance production of hematopoietic cells in a mammal, including without limitation an aged mammal, by selective depletion of myeloid-biased hematopoietic stem cells (m...
|
|
WO/2024/096014A1 |
The purpose of the present invention is to provide a novel TRPA1 agonist. The present invention relates to a composition for activating TRPA1, comprising a mushroom extract or lenthionine. The composition can enhance appetite and food ...
|
|
WO/2024/096122A1 |
The present disclosure provides a microbiome for the purpose of improving the response rate of an immune checkpoint inhibitor. Specifically, the present disclosure provides a microorganism wherein at least one gene among a flagella-formi...
|
|
WO/2024/096516A1 |
The present invention relates to a composition for transpulmonary delivery of nucleic acid drugs and a use thereof. The composition for transpulmonary delivery of the present invention is specific to lung tissue and specific cells thereo...
|
|
WO/2024/090941A1 |
The present invention relates to a composition for the prevention, amelioration or treatment of an anterior segment eye disease, the composition comprising a plant extract of the genus Aloe as an active ingredient. When the Aloe vera ext...
|
|
WO/2024/090549A1 |
Provided is an agent for preventing or ameliorating neuropathy caused by decreased nerve function due to nerve damage or diabetic neuropathy. The agent for preventing or ameliorating neuropathy is obtained by combining one or more lact...
|
|
WO/2024/090341A1 |
The purpose of the present invention is to provide an anti-aging agent which exhibits an excellent effect such as a mitochondria activating effect. The anti-aging agent according to the present invention is characterized by containing an...
|
|
WO/2024/091932A1 |
The present disclosure provides methods of preventing, lessening the effects, or treating sepsis comprising administering a prophylactically effective amount of defibrotide to a subject in need thereof.
|
|
WO/2024/090329A1 |
The present inventors have found that a pyridoxal synthetic enzyme Pyridoxamine-5'-phosphate oxidase (PNPO) acts as an oxygen sensing mechanism for a novel pathway that is independent from an HIF pathway in chronic hypoxia. A pharmaceuti...
|
|
WO/2024/091451A1 |
Disclosed herein are compositions and methods useful for the treatment or amelioration of various diseases, disorders, or conditions. Some aspects pertain to a pharmaceutical composition comprising 17-ethynyl-10R, 13S-dimethyl 2, 3, 4, 7...
|
|
WO/2024/092166A1 |
A method and composition for enhancing adenosine monophosphate-activated protein kinase (AMPK) activity and improving mitochondrial-related oxidative metabolic parameters in both exercising and sedentary mammals through oral ingestion of...
|
|
WO/2024/091036A1 |
The present invention relates to a composition for treatment of mitochondrial transplantation for immunomodulation and fibrosis control in multiple sclerosis. The present invention confirmed that, when muscle-derived mitochondria are tra...
|
|
WO/2024/090589A1 |
The present invention provides a composition for preventing finger sucking, the composition being applicable to nails and comprising denatonium benzoate and sorbitol. According to the present invention, the bitter taste of the compositio...
|
|
WO/2024/089454A1 |
The present invention relates to a composition, preferably a nutraceutical composition, for use in a method of treatment of post viral infection caused by the virus strain called SARS-CoV-2, or alternatively COVID- 19, chronic fatigue/fa...
|
|
WO/2024/090521A1 |
Provided is a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy, the composition containing a retinoic acid receptor (RAR) agonist.
|
|
WO/2024/087834A1 |
The present invention relates to a composition comprising a growth hormone fusion protein and a use thereof. The composition comprises: the growth hormone fusion protein and at least one of a buffering agent and a protective agent; a use...
|
|
WO/2024/090800A1 |
A lipocalin 2 Inhibitor of the present invention can exhibit the effects of preventing and treating liver fibrosis by inhibiting the induction of liver cells into hepatic stellate cells through the inhibition of lipocalin 2 expression, a...
|
|
WO/2024/090548A1 |
Provided are novel composite materials which contain hydroxyapatite particles and which make it possible to more effectively utilize the activity of the hydroxyapatite particles. An embodiment of the present invention is a hydroxyapatite...
|
|
WO/2024/091007A1 |
The present invention relates to a novel compound and a pharmaceutical composition including same as an active ingredient for the prevention or treatment of pulmonary fibrosis. Specifically, the present invention relates to a compound re...
|
|
WO/2024/091484A1 |
Disclosed are synthetic amniotic fluid compositions comprising ulin-A- statin/urinary trypsin inhibitor (UTI) and ascorbic acid and methods of using the disclosed synthetic amniotic fluid compositions, which may be useful for a variety o...
|
|
WO/2024/084070A1 |
The present invention concerns screening methods to identify compounds that regulate the activity of Acinetobacter baumannii SpoT enzyme, in particular compounds that are able to partially or completely inhibit the hydrolase activity of ...
|
|
WO/2024/085143A1 |
The purpose of the present invention is to provide a novel peptide that could be used to induce an immune response to SARS-CoV-2. A nucleocapsid-derived antigen peptide according to the present disclosure includes the following polypep...
|
|
WO/2024/084785A1 |
The purpose of the present invention is to provide a composition having higher efficacy and safety and suitable for use as a RS virus vaccine. Provided is a composition containing G protein and a CpG oligodeoxynucleotide of a RS virus,...
|
|
WO/2024/085182A1 |
The present invention addresses the problem of providing a novel method for treating T cell tumor, whereby it becomes possible to induce the cell damage of a tumor cell and which is less likely to cause immunodeficiency. According to t...
|
|
WO/2024/085325A1 |
The present invention relates to a composition for alleviating, preventing, or treating diseases related to peritoneal fibrosis, comprising tiplaxtinin. The tiplaxtinin of the present invention has an excellent peritoneal EMT inhibitory ...
|
|
WO/2024/085245A1 |
The purpose of the present invention is to provide a preparation that can effectively suppress post-operative delirium. A post-operative delirium suppressant according to the present invention is characterized by containing a GABA-A rece...
|
|
WO/2024/085261A1 |
Provided are: a novel microparticle that includes miRNA for controlling the production of nitric oxide and that is an agent for promoting the production of nitric oxide, said microparticle being capable of controlling the expression of a...
|
|
WO/2024/086835A1 |
The present disclosure relates to methods for treating blood transfusion-dependent hematological malignancy patients with oxygen reduced blood.
|
|
WO/2024/084360A1 |
The present invention relates to compounds of Formula A, and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such proce...
|
|
WO/2024/084744A1 |
An oral formulation comprising, as an active ingredient, nicotinamide mononucleotide in the form of a liposome.
|
|
WO/2024/085085A1 |
[Problem] To provide a method for producing a dendritic cell formulation that stimulates NKT cells, from monocytes collected from a recipient (monocytes collected by apheresis or peripheral blood containing monocytes), and that can exhib...
|
|
WO/2024/084400A2 |
The present disclosure relates generally to alpha 2 macroglobulin (A2M) protein and soluble Klotho (sKL) protein, compositions comprising same, and related uses (e.g., treating a coronavirus (e.g., severe acute respiratory syndrome coron...
|
|
WO/2024/083176A1 |
Disclosed are the uses of amniotic fluid in the preparation of a drug for treating and/or preventing macrophage-mediated diseases, a drug for treating and/or preventing type M1 macrophage-mediated diseases, a drug for treating and/or pre...
|
|
WO/2024/085618A1 |
The present invention relates to: a pharmaceutical composition for preventing or treating Melas syndrome; and the like, and has been completed by identifying that an isopquinoline derivative, discovered through mitophagy activity-based s...
|
|
WO/2024/086834A1 |
The present disclosure relates to methods for treating burn patients with oxygen reduced blood.
|
|
WO/2024/083820A1 |
Inventors have used three cohorts of horses: a cohort consisting of healthy horses (n=20), a cohort consisting of horses hospitalized for colic without signs of sepsis until discharge (n=17) and horses hospitalized for colic with signs o...
|
|
WO/2024/084852A1 |
The present invention relates to a nucleic acid molecule having a nucleotide sequence that encodes a chimeric antigen receptor (CAR). The present invention relates to a vector containing said nucleic acid molecule. The present invention ...
|
|
WO/2024/085637A1 |
The present invention relates to a composition for preventing aging and use of the composition, the composition comprising GCLC, ENO1, Map1s, KNG1 and various combinations thereof, derived from plasma treated with Oct4, Sox2, Klf4, and c...
|
|
WO/2024/081018A1 |
The subject invention pertains to compounds and compositions comprising one or more inhibitor of DDX3 and methods for suppressing fibrosis by administration of one or more DDX3 inhibitor to a subject or in an in vitro setting.
|
|
WO/2024/080371A1 |
This blood coagulation time shortening agent for a blood specimen deficient in coagulation factor XII for activated partial thromboplastin time measurement uses, as an active ingredient, a polymer having 2-methacryloyloxyethyl phosphoryl...
|
